Calcineurin‐Inhibitor Discontinuation Could Reduce the Risk of De Novo Malignancies After Liver Transplantation for Alcohol‐Related Liver Disease
Clinical Transplantation · 2024
DOI: 10.1111/ctr.70014 ↗At a glance
Journal article in Clinical Transplantation, 2024. Written by Domitille Erard and 8 co-authors. Institution: Service d'hépatologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France. Major MEDLINE topics: Liver Transplantation, Calcineurin Inhibitors, Liver Diseases, Alcoholic, Neoplasms. Cited 1 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
De novo malignancies are one of the leading causes of death after liver transplantation (LT), particularly in patients transplanted for alcohol‐related liver disease (ALD). This retrospective study aimed to assess risk factors for malignancies and to evaluate the impact of calcineurin inhibitor (CNI) discontinuation.
Methods
From 1990 to 2015, all patients transplanted for ALD were included.
Results
A total of 493 patients were included, 77.9% were male and the median age at LT was 54 years. After LT, 278 de novo malignancies were diagnosed in 214 patients (43.4%). The cumulative incidence of de novo malignancies was 16.3% at 5 years, 34.4% at 10 years, and 49.8% at 15 years. In multivariate analysis, the independent risk factors were male gender (HR = 1.6), and active or weaned smoking (HR = 2.0). Discontinuation of CNI was a protective factor (HR = 0.6). Survival after diagnosis of de novo malignancy was 42.7% at 5 years and 27.5% at 10 years.
Conclusion
Our results confirm the major incidence of de novo malignancies after LT for ALD, as well as the important role of non‐modifiable risk factors such as smoking and gender. CNI discontinuation is a protective factor, and the only adaptable, and could be proposed in smoker male patients transplanted for ALD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Service d'hépatologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.
- Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
- Université Claude Bernard Lyon 1, Lyon, France.
ORCID profiles: Domitille Erard, Jérôme Dumortier
Cite
APA
Erard, D., Steiner, A., Boillot, O., Thimonier, E., Vallin, M., Veyre, F., Guillaud, O., Radenne, S., & Dumortier, J. (2024). Calcineurin‐Inhibitor Discontinuation Could Reduce the Risk of De Novo Malignancies After Liver Transplantation for Alcohol‐Related Liver Disease. Clinical Transplantation. https://doi.org/10.1111/ctr.70014
Vancouver
Erard D, Steiner A, Boillot O, Thimonier E, Vallin M, Veyre F, et al. Calcineurin‐Inhibitor Discontinuation Could Reduce the Risk of De Novo Malignancies After Liver Transplantation for Alcohol‐Related Liver Disease. Clinical Transplantation. 2024. doi:10.1111/ctr.70014
BibTeX
@article{Erard2024,
author = {Erard, Domitille and Steiner, Anouk and Boillot, Olivier and Thimonier, Elsa and Vallin, Mélanie and Veyre, Florian and Guillaud, Olivier and Radenne, Sylvie and Dumortier, Jérôme},
title = {Calcineurin‐Inhibitor Discontinuation Could Reduce the Risk of De Novo Malignancies After Liver Transplantation for Alcohol‐Related Liver Disease},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.70014}
}
EUVIMED